Circadian effects in cancer-relevant psychoneuroendocrine and immune pathways

Psychoneuroendocrinology

Volumn 35, Issue 7, 2010, Pages 963-976

  Eismann, Emily A ^a   Lush, Elizabeth ^a   Sephton, Sandra E ^a  

^a UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Cancer; Circadian rhythm; Endocrine; Immune; Psychosocial; Stress

Indexed keywords

CANCER VACCINE; CATECHOLAMINE; CYTOKINE; GLUCOCORTICOID; HYDROCORTISONE; MELATONIN; PER1 PROTEIN; PER2 PROTEIN; TRANSCRIPTION FACTOR;

ADAPTIVE IMMUNITY; ADVANCED CANCER; BREAST CANCER; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER INVASION; CANCER SUSCEPTIBILITY; CELL THERAPY; CELLULAR IMMUNITY; CHRONIC STRESS; CHRONOTHERAPY; CIRCADIAN RHYTHM; CIRCADIAN RHYTHM SLEEP DISORDER; COLORECTAL CANCER; DOWN REGULATION; ENDOCRINE DISEASE; ENDOMETRIUM CANCER; GENE CONTROL; GENE EXPRESSION REGULATION; GROWTH RATE; HORMONAL REGULATION; HORMONE ACTION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOCOMPROMISED PATIENT; INFLAMMATION; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MENTAL DISEASE; MENTAL STRESS; METASTASIS; NEUROENDOCRINE SYSTEM; NEUROPSYCHIATRY; NONHUMAN; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SLEEP WAKING CYCLE; SOCIAL PSYCHOLOGY; SUPRACHIASMATIC NUCLEUS; T LYMPHOCYTE; TUMOR VASCULARIZATION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CHRONOBIOLOGY DISORDERS; CIRCADIAN RHYTHM; ENDOCRINE GLANDS; HUMANS; MICE; NEOPLASMS; NERVOUS SYSTEM; RATS;

EID: 77954954056     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2009.12.011     Document Type: Review

References (196)

1. Abercrombie H., Giese-Davis J., Sephton S., Epel E., Turner-Cobb J., Spiegel D. Flattened cortisol rhythms in metastatic breast cancer patients. Psychoneuroendocrinology 2004, 29:1082-1092.
2. Abrahamson E., Moore R. Suprachiasmatic nucleus in the mouse: retinal innervation, intrinsic organization and efferent projections. Brain Res. 2001, 916:172-191.
3. Ancoli-Israel S., Liu L., Marler M., Parker B., Jones V., Sadler G. Fatigue, sleep, and circadian rhythms prior to chemotherapy for breast cancer. Support. Care Cancer 2006, 14:201-209.
4. Andersen B., Farrar W., Golden-Kreutz D., Kutz L., MacCallum R., Courtney M. Stress and immune responses after surgical treatment for regional breast cancer. J. Natl. Cancer Inst. 1998, 90:30-36.
5. Anisimov V. The role of pineal gland in breast cancer development. Crit. Rev. Oncol. Hematol. 2003, 46:221-234.
6. Antoni M., Lutgendorf S., Cole S., Dhabhar F., Sephton S., McDonald P. The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat. Rev. Cancer 2006, 6:240-248.
7. Aragona M., Muscatello M., Losi E., Panetta S., La Torre F., Pastura G. Lymphocyte number and stress parameter modifications in untreated breast cancer patients with depressive mood and previous life stress. J. Exp. Therapeut. Oncol. 1996, 1:354-360.
8. Archer S., Viola A., Kyriakopoulou V., von Schantz M., Dijk D. Inter-individual differences in habitual sleep timing and entrained phase of endogenous circadian rhythms of BMAL1, PER2 and PER3 mRNA in human leukocytes. Sleep 2008, 31:608-617.
9. Arjona A., Sarkar D. Circadian oscillations of clock genes, cytolytic factors, and cytokines in rat NK cells. J. Immunol. 2005, 174:7618-7624.
10. Armaiz-Pena G., Lutgendorf S., Cole S., Sood A. Neuroendocrine modulation of cancer progression. Brain Behav. Immun. 2009, 23:10-15.
11. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357:539-545.
12. Balsalobre A., Brown S., Marcacci L., Tronche F., Kellendonk C., Reichardt H. Resetting of circadian time in peripheral tissues by glucocorticoid signaling. Science 2000, 289:2344-2347.
13. Ben-Eliyahu S., Page G., Yirmiya R., Shakhar G. Evidence that stress and surgical interventions promote tumor development by suppressing natural killer cell activity. Int. J. Cancer 1999, 80:880-888.
14. Ben-Eliyahu S., Shakhar G., Page G., Stefanski V., Shakhar K. Suppression of NK cell activity and of resistance to metastasis by stress: a role for adrenal catecholamines and β-adrenoceptors. Neuroimmunomodulation 2000, 8:154-164.
15. Blake-Mortimer J., Sephton S., Carlson R., Stites D., Spiegel D. Cytotoxic T lymphocyte count and survival time in women with metastatic breast cancer. Breast J. 2004, 10:195-199.
16. Born J., Lange T., Hansen K., Molle M., Fehm H. Effects of sleep and circadian rhythm on circulating immune cells. J. Immunol. 1997, 158:4454-4464.
17. Bower J., Ganz P.A., Aziz N. Altered cortisol response to psychologic stress in breast cancer survivors with persistent fatigue. Psychosom. Med. 2005, 67:277-280.
18. Bower J., Ganz P., Aziz N., Fahey J. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom. Med. 2002, 64:604-611.
19. Bower J., Ganz P., Dickerson S., Petersen L., Aziz N., Fahey J. Diurnal cortisol rhythm and fatigue in breast cancer survivors. Psychoneuroendocrinology 2005, 30:92-100.
20. Brigati C., Noonan D., Albini A., Benelli R. Tumors and inflammatory infiltrates: friends or foes?. Clin. Exp. Metastasis 2002, 19:247-258.
21. Buckley T., Schatzberg A. Review: on the interactions of the hypothalamic-pituitary-adrenal (HPA) axis and sleep: normal HPA axis activity and circadian rhythm, exemplary sleep disorders. J. Clin. Endocrinol. Metab. 2005, 90:3106-3114.
22. Burgess C., Cornelius V., Love S., Graham J., Richards M., Ramirez A. Depression and anxiety in women with early breast cancer: Five year observational cohort study. Br. Med. J. 2005, 330:702-705.
23. Cakir Y., Plummer H., Tithof P., Schuller H. Beta-adrenergic and arachidonic acid-mediated growth regulation of human breast cancer cell lines. Int. J. Oncol. 2002, 21:153-157.
24. Canaple L., Kakizawa T., Laudet V. The days and nights of cancer cells. Cancer Res. 2003, 63:7545-7552.
25. Caplette-Gingras A., Savard J. Depression in women with metastatic breast cancer: a review of the literature. Palliat. Support. Care 2008, 6:377-387.
26. Capuron L., Miller A. Cytokines and psychopathology: lessons from interferon-alpha. Biol. Psychiatr. 2004, 56:819-824.
27. Carlson L., Campbell T., Garland S., Grossman P. Associations among salivary cortisol, melatonin, catecholamines, sleep quality and stress in women with breast cancer and healthy controls. J. Behav. Med. 2007, 30:45-58.
28. Caufriez A., Moreno-Reyes R., Leproult R., Vertongen F., Van Cauter E., Copinschi G. Immediate effects of an 8-h advance shift of the rest-activity cycle on 24-h profiles of cortisol. Am. J. Physiol. Endocrinol. Metab. 2002, 282:E1147-E1153.
29. Cavadini G., Petrzilka S., Kohler P., Jud C., Tobler I., Birchler T. TNF-α suppresses the expression of clock genes by interfering with E-box-mediated transcription. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:12843-12848.
30. Charmandari E., Tsigos C., Chrousos G. Endocrinology of the stress response. Ann. Rev. Physiol. 2005, 67:259-284.
31. Chrousos G., Gold P. A healthy body in a healthy mind-and vice versa-the damaging power of " uncontrollable" stress. J. Clin. Endocrinol. Metab. 1998, 83:1842-1845.
32. Coogan A., Wyse C. Neuroimmunology of the circadian clock. Brain Res. 2008, 1232:104-112.
33. Dantzer R., O'Connor J., Freund G., Johnson R., Kelley K. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 2008, 9:46-57.
34. Davis S., Mirick D., Stevens R. Night shift work, light at night, and risk of breast cancer. J. Natl. Cancer Inst. 2001, 93:1557-1562.
35. Del Gobbo V., Libri V., Villani N., Calio R., Nistico G. Pinealectomy inhibits interleukin-2 production and natural killer activity in mice. Int. J. Immunopharmacol. 1989, 11:567-573.
36. Dhabhar F. Enhancing versus suppressive effects of stress on immune function: implications for immunoprotection and immunopathology. Neuroimmunomodulation 2009, 16:300-317.
37. Dhabhar F., McEwen B. Acute stress enhances while chronic stress suppresses cell-mediated immunity in vivo: a potential role for leukocyte trafficking. Brain Behav. Immun. 1997, 11:286-306.
38. Dhabhar F., Miller A., Stein M., McEwen B., Spencer R. Diurnal and acute stress-induced changes in distribution of peripheral blood leukocyte subpopulations. Brain Behav. Immun. 1994, 8:66-79.
39. Dickmeis T. Glucocorticoids and the circadian clock. J. Endocrinol. 2009, 200:3-22.
40. Dinges D., Douglas S., Zaugg L., Campbell D., McMann J., Whitehouse W. Leukocytosis and natural killer cell function parallel neurobehavioral fatigue induced by 64hours of sleep deprivation. J. Clin. Invest. 1994, 93:1930-1939.
41. Dubocovich M., Benloucif S., Masana M. Melatonin receptors in the mammalian suprachiasmatic nucleus. Behav. Brain Res. 1996, 73:141-147.
42. Dunn G., Old L., Schreiber R. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004, 21:137-148.
43. Du-Quiton J., Wood P., Burch J., Grutsch J., Gupta D., Tyer K. Actigraphic assessment of daily sleep-activity pattern abnormalities reflects self-assessed depression and anxiety in outpatients with advanced non-small cell lung cancer. Psycho-Oncology 2009, 18. n/a.
44. Elenkov I. Systemic stress-induced Th2 shift and its clinical implications. Int. Rev. Neurobiol. 2002, 52:163-186.
45. Elenkov I., Chrousos G. Stress hormones, Th1/Th2 patterns, pro/anti-inflammatory cytokines and susceptibility to disease. Trends Endocrinol. Metab. 1999, 10:359-368.
46. Everson C. Clinical assessment of blood leukocytes, serum cytokines, and serum immunoglobulins as responses to sleep deprivation in laboratory rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2005, 289:R1054-R1063.
47. Felten D. Neurotransmitter signaling of cells of the immune system: important progress, major gaps. Brain Behav. Immun. 1991, 5:2-8.
48. Filipski E., King V., Li X., Granda T., Mormont M., Liu X. Host circadian clock as a control point in tumor progression. J. Natl. Cancer Inst. 2002, 94:690-697.
49. Filipski E., Li X., Lévi F. Disruption of circadian coordination and malignant growth. Cancer Causes Control. 2006, 17:509-514.
50. Fortner B., Stepanski E., Wang S., Kasprowicz S., Durrence H. Sleep and quality of life in breast cancer patients. J. Pain Symptom Manage. 2002, 24:471-480.
51. Fu L., Lee C. The circadian clock: pacemaker and tumor suppressor. Nature 2003, 3:350-360.
52. Fu L., Pelicano H., Liu J., Huang P., Lee C. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 2002, 111:41-50.
53. Gatti G., Cavallo R., Sartori M. Inhibition by cortisol of human natural killer (NK) cell activity. J. Steroid Biochem. 1987, 26:49-58.
54. Gery S., Komatsu N., Baldjyan L., Yu A., Koo D., Koeffler H. The circadian gene Per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol. Cell 2006, 22:375-382.
55. Gery S., Virk R., Chumakov K., Yu A., Koeffler H. The clock gene Per2 links the circadian system to the estrogen receptor. Oncogene 2007, 26:7916-7920.
56. Giese-Davis J., DiMiceli S., Sephton S., Spiegel D. Emotional expression and diurnal cortisol slope in women with metastatic breast cancer in supportive-expressive group therapy: a preliminary study. Biol. Psychol. 2006, 73:190-198.
57. Giese-Davis J., Sephton S., Abercrombie H., Duran R., Spiegel D. Repression and high anxiety are associated with aberrant diurnal cortisol rhythms in women with metastatic breast cancer. Health Psychol. 2004, 23:645-650.
58. Gillis S., Crabtree G., Smith K. Glucocorticoid-induced inhibition of T cell growth factor production. II. The effect on the in vitro generation of cytolytic T cells. J. Immunol. 1979, 123:1632-1638.
59. Glaser R. Stress-associated immune dysregulation and its importance for human health: a personal history of psychoneuroimmunology. Brain Behav. Immun. 2005, 19:3-11.
60. Glaser R., Kiecolt-Glaser J. Stress-induced immune dysfunction: implications for health. Nat. Rev. Immunol. 2005, 5:243-251.
61. Gorsch S., Memoli V., Stukel T., Gold L., Arrick B. Immunohistochemical staining for transforming growth factor B1 associates with disease progression in human breast cancer. Cancer Res. 1992, 52:6949-6952.
62. Green C., Takahashi J., Bass J. The meter of metabolism. Cell 2008, 134:728-742.
63. Guess J., Burch J., Ogoussan K., Armstead C., Zhang H., Wagner S. Circadian disruption, Per3, and human cytokine secretion. Integr. Cancer Ther. Epub 2009.
64. Guillaumond F., Dardente H., Giguere V., Cermakian N. Differential control of Bmal1 circadian transcription by REV-ERB and ROR nuclear receptors. J. Biol. Rhythms 2005, 20:391-440.
65. Guo H., Brewer J., Champhekar A., Harris R., Bittman E. Differential control of peripheral circadian rhythms by suprachiasmatic-dependent neural signals. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:3111-3116.
66. Harbuz M., Stephanou A., Sarlis N., Lightman S. The effects of recombinant human interleukin (IL)-1α, IL-1β or IL-6 on hypothalamo-pituitary-adrenal axis activation. J. Endocrinol. 1992, 133:349-355.
67. Harris R., Alshafie G., Abou-Issa H., Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res. 2000, 60:2101-2103.
68. Honma S., Shimodaira K., Shimizu Y., Tsuchiya N., Saito H., Yanaihara T., Okai T. The influence of inflammatory cytokines on estrogen production and cell proliferation in human breast cancer cells. Endocr. J. 2002, 49:371-377.
69. Hudson J., Shoaibi M., Maestro R., Carnero A., Hannon G., Beach D. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J. Exp. Med. 1999, 190:1375-1382.
70. Innominato P., Focan C., Gorlia T., Moreau T., Garufi C., Waterhouse J. Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer. Cancer Res. 2009, 69:4700-4707.
71. Irwin M. Human psychoneuroimmunology: 20 years of discovery. Brain Behav. Immun. 2008, 22:129-139.
72. Irwin M., McClintick J., Costlow C., Fortner M., White J., Gillin J. Partial night sleep deprivation reduces natural killer and cellular immune responses in humans. FASEB J. 1996, 10:643-653.
73. Irwin M., Wang M., Campomayor C., Collado-Hidalgo A., Cole S. Sleep deprivation and activation of morning levels of cellular and genomic markers of inflammation. Arch. Intern. Med. 2006, 166:1756-1762.
74. Jacobsen P., Massie M., Kinne D., Holland J. Hypnotic efficacy and safety of triazolam administered during the postoperative period. Gen. Hosp. Psychiatr. 1994, 16:419-425.
75. Jaiswal M., LaRusso N., Burgart L., Gores G. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res. 2000, 60:184-190.
76. Jehn C., Kuehnhardt D., Bartholomae A., Pfeiffer S., Krebs M., Regierer A. Biomarkers of depression in cancer patients. Cancer 2006, 107:2723-2729.
77. Jiang X., Yang D., Elliott R., Head J. Reduction in serum IL-6 after vaccination of breast cancer patients with tumour-associated antigens is related to estrogen receptor status. Cytokine 2000, 12:458-465.
78. Joyce J., Pollard J. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 2009, 9:239-252.
79. Kalsbeek A., Palm I., La Fleur S., Scheer F., Perreau-Lenz S., Ruiter M. SCN outputs and the hypothalamic balance of life. J. Biol. Rhythm 2006, 21:458-469.
80. Kaplan D., Shankaran V., Dighe A., Stockert E., Aguet M., Old L. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:7556-7561.
81. Kemeny M., Schedlowski M. Understanding the interaction between psychosocial stress and immune-related diseases: a stepwise progression. Brain Behav. Immun. 2007, 21:1009-1018.
82. Kim R., Emi M., Tanabe K. Cancer immunosuppression and autoimmune disease: Beyond immunosuppressive networks for tumor immunity. Immunology 2006, 119:254-264.
83. Kissane D., Grabsch B., Love A., Clarke D., Bloch S., Smith G. Psychiatric disorder in women with early stage and advanced breast cancer: a comparative analysis. Aust. New Zealand J. Psychiatry 2004, 38:320-326.
84. Koyanagi S., Ohdo S. Alteration of intrinsic biological rhythms during interferon treatment and its possible mechanism. Mol. Pharmacol. 2002, 62:1393-1399.
85. Kozlowski L., Zakrzewska I., Tokajuk P., Wojtukiewicz M. Concentration of interleukin-6 (Il-6), interleukin-8 (Il-8) and interleukin-10 (Il-10) in blood serum of breast cancer patients. Roczniki Akademii Medycznej w Bialymstoku 2003, 48:82-84.
86. Kronfol Z., Nair M., Zhang Q., Hill E., Brown M. Circadian immune measures in healthy volunteers: relationship to hypothalamic-pituitary-adrenal axis hormones and sympathetic neurotransmitters. Psychosom. Med. 1997, 59:42-50.
87. Kubo T., Ozasa K., Mikami K., Wakai K., Fujino Y., Watanabe Y. rospective cohort study of the risk of prostate cancer among rotating-shift workers: findings from the Japan collaborative cohort study. Am. J. Epidemiol. 2006, 164:549-555.
88. Kudo Y., Uchiyama M., Okawa M., Shibui K., Kamei Y., Hayakawa T. Correlation between the circadian sleep propensity rhythm and hormonal rhythms under ultra-short sleep-wake cycle. Psychiatr. Clin. Neurosci. 1999, 53:253-255.
89. Kusanagi H., Hida A., Satoh K., Echizenya M., Shimizu T., Pendergast J. Expression profiles of 10 circadian clock genes in human peripheral blood mononuclear cells. Neurosci. Res. 2008, 61:136-142.
90. Kusanagi H., Mishima K., Satoh K., Echizenya M., Katoh T., Shimizu T. Similar profiles in human period1 gene expression in peripheral mononuclear and polymorphonuclear cells. Neurosci. Lett. 2004, 365:124-127.
91. Kwak Y., Lundkvist G., Brask J., Davidson A., Menaker M., Kristensson K. Interferon-γ alters electrical activity and clock gene expression in suprachiasmatic nucleus neurons. J. Biol. Rhythm 2008, 23:150-159.
92. Lal P., Tan L., Chen B. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am. J. Clin. Pathol. 2005, 123:541-546.
93. Lanier L. On guard-activating NK cell receptors. Nat. Immunol. 2001, 2:23-27.
94. Lazarus R., Folkman S. Stress, Appraisal, and Coping 1984, Springer, New York.
95. Leproult R., Copinschi G., Buxton O., Van Cauter E. Sleep loss results in an elevation of cortisol levels the next evening. Sleep 1997, 20:865-870.
96. Lévi F. From circadian rhythms to cancer chronotherapeutics. Chronobiol. Int. J. Biol. Med. Rhythm Res. 2002, 19:1-19.
97. Lévi F., Benavides M., Chevelle C., Le Saunier F., Bailleul F., Misset J. Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity. J. Clin. Oncol. 1990, 8:705-714.
98. Lévi F., Zidani R., Misset J. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997, 350:681-686.
99. Levin R., Daehler M., Grutsch J., Quiton J., Lis C., Peterson C. Circadian function in patients with advanced non-small-cell lung cancer. Br. J. Cancer 2005, 93:1202-1208.
100. Lewy A., Emens J., Songer J., Sims N., Laurie A., Fiala S. Winter depression: integrating mood, circadian rhythms, and the sleep/wake and light/dark cycles into a bio-psycho-social-environmental model. Sleep Med. Clin. 2009, 4:285-299.
101. Lippman M., Dickson R., Bates S., Knabbe C., Huff K., Swain S. Autocrine and paracrine growth regulation of human breast cancer. Breast Cancer Res. Treat. 1986, 7:59-70.
102. Lissoni P. Is there a role for melatonin in supportive care?. Support. Care Cancer 2002, 10:110-116.
103. Liu C., Weaver D., Jin X., Shearman L., Pieschl R., Gribkoff V. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron 1997, 19:91-102.
104. Liu J., Mankani G., Shi X., Meyer M., Cunningham-Runddles S., Ma X. The circadian clock Period 2 gene regulates gamma interferon production of NK cells in host response to lipopolysaccharide-induced endotoxic shock. Infect. Immun. 2006, 74:4750-4756.
105. Liu L., Marler M., Parker B., Jones V., Johnson S., Cohen-Zion M. The relationship between fatigue and light exposure during chemotherapy. Support. Care Cancer 2005, 13:1010-1017.
106. Liyanage U., Moore T., Joo H., Tanaka Y., Herrmann V., Doherty G. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immun. 2002, 169:2756-2761.
107. Luecken L., Dausch B., Gulla V., Hong R., Compas B. Alterations in morning cortisol associated with PTSD in women with breast cancer. J. Psychosom. Res. 2004, 56:13-15.
108. Lundkvist G., Hill R., Kristensson K. Disruption of circadian rhythms in synaptic activity of the suprachiasmatic nuclei by African trypanosomes and cytokines. Neurobiol. Dis. 2002, 11:20-27.
109. Lutgendorf S., Cole S., Costanzo E., Bradley S., Coffin J., Jabbari S. Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin. Cancer Res. 2003, 9:4514-4521.
110. Lutgendorf S., Costanzo E. Psychoneuroimmunology and health psychology: an integrative model. Brain Behav. Immun. 2003, 17:225-232.
111. Lutgendorf S., Sood A., Anderson B., McGinn S., Maiseri H., Dao M. Social support, psychological distress, and natural killer cell activity in ovarian cancer. J. Clin. Oncol. 2005, 23:7105-7113.
112. MacFarlane J., Cleghorn J., Brown G. Melatonin and core temperature rhythms in chronic insomnia. Adv. Biosci. 1984, 53:301-306.
113. Madden K. Catecholamines, sympathetic innervation, and immunity. Brain Behav. Immun. 2003, 17:S5-S10.
114. Madhusudan S., Foster M., Muthuramalingam S., Braybrooke J., Wilner S., Kaur K. A phase II study of Etanercept (Enbrel), a tumor necrosis factor α inhibitor in patients with metastatic breast cancer. Clin. Cancer Res. 2004, 10:6528-6534.
115. Mantovani A., Sozzani S., Locati M., Schioppa T., Saccani A., Allavena P. Infiltration of tumours by macrophages and dendritic cells: tumour-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Novartis Found. Symp. 2004, 256:137-145.
116. Marchetti B., Spinola P., Pelletier G., Labrie F. A potential role for catecholamines in the development and progression of carcinogen-induced mammary tumors: hormonal control of β-adrenergic receptors and correlation with tumor growth. J. Steroid Biochem. Mol. Biol. 1991, 38:307-320.
117. Mazzoccoli G., Carughi S., De Cata A., La Viola M., Giuliani A., Tarquini R. Neuroendocrine alterations in lung cancer patients. Neuro. Endocrinol. Lett. 2003, 24:77-82.
118. McEwen B. Protection and damage from acute and chronic stress: Allostasis and allostatic overload and relevance to the pathophysiology of psychiatric disorders. Ann. N.Y. Acad. Sci. 2004, 1032:1-7.
119. McGregor B., Antoni M. Psychological intervention and health outcomes among women treated for breast cancer: a review of stress pathways and biological mediators. Brain Behav. Immun. 2009, 23:150-166.
120. Meerlo P., de Boer S., Koolhaas J., Daan S., Van den Hoofdakker R. Changes in daily rhythms of body temperature and activity after a single social defeat in rats. Physiol. Behav. 1996, 59:735-739.
121. Meerlo P., Sgoifo A., de Boer S., Koolhaas J. Long-lasting consequences of a social conflict in rats: Behavior during the interaction predicts subsequent changes in daily rhythms of heart rate, temperature, and activity. Behav. Neurosci. 1999, 113:1283-1290.
122. Meier-Ewert H., Ridker P., Rifai N., Regan M., Price N., Dinges D. Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk. J. Am. Coll. Cardiol. 2004, 43:678-683.
123. Miller A., Ancoli-Israel S., Bower J., Capuron L., Irwin M. Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J. Clin. Oncol. 2008, 26:971-982.
124. Miller G., Chen E., Zhou E. If it goes up, must it come down? Chronic stress and the hypothalamic-pituitary-adrenocortical axis in humans. Psychol. Bull. 2007, 133:25-45.
125. Mills P., Parker B., Dimsdale J., Sadler G., Ancoli-Israel S. The relationship between fatigue and quality of life and inflammation during anthracycline-based chemotherapy in breast cancer. Biol. Psychol. 2005, 69:85-96.
126. Mongrain V., Cermakian N. Clock genes in health and diseases. J. Appl. Biomed. 2009, 7:15-33.
127. Mormont M., Lévi F. Circadian-system alterations during cancer processes: a review. Int. J. Cancer 1997, 70:241-247.
128. Mormont M., Waterhouse J., Bleuzen P., Giacchetti S., Jami A., Bogdan A. Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin. Cancer Res. 2000, 6:3038-3045.
129. Murillo-Rodríguez E., Arias-Carrión O., Sanguino-Rodríguez K., González-Arias M., Haro R. Mechanisms of sleep-wake cycle modulation. CNS Neurol. Disord. Drug Targets 2009, 8:245-253.
130. Mystakidou K., Parpa E., Tsilika E., Gennatas C., Galanos A., Vlahos L. How is sleep quality affected by the psychological and symptom distress of advanced cancer patients?. Palliat. Med. 2009, 23:46-53.
131. Nagoshi E., Saini C., Bauer C., Laroche T., Naef F., Schibler U. Circadian gene expression in individual fibroblasts: cell-autonomous and self-sustained oscillators pass time to daughter cells. Cell 2004, 119:693-705.
132. Nishimura R., Nagao K., Miyayama H., Matsuda M., Baba K., Matsuoka Y. An analysis of serum interleukin-6 levels to predict benefits of medroxyprogesterone acetate in advanced or recurrent breast cancer. Oncology 2000, 59:166-173.
133. Ostrand-Rosenberg S. Immune surveillance: a balance between protumor and antitumor immunity. Curr. Opin. Genet. Dev. 2008, 18:11-18.
134. Palesh O., Zeitzer J., Conrad A., Giese-Davis J., Mustian K., Popek V. Vagal regulation, cortisol, and sleep disruption in women with metastatic breast cancer. J. Clin. Sleep Med. 2008, 4:441-449.
135. Parker K., Bliwise D., Ribeiro M., Jain S., Vena C., Kohles-Baker K. Sleep/wake patterns of individuals with advanced cancer measured by ambulatory polysomnography. J. Clin. Oncol. 2008, 26:2464-2472.
136. Pati A., Parganiha A., Kar A., Soni R., Roy S., Choudhary V. Alterations of the characteristics of the circadian rest-activity rhythm of cancer in-patients. Chronobiol. Int. J. Biol. Med. Rhythm Res. 2007, 24:1179-1197.
137. Payne J., Held J., Thorpe J., Shaw H. Effect of exercise on biomarkers, fatigue, sleep disturbances, and depressive symptoms in older women with breast cancer receiving hormonal therapy. Oncol. Nurs. Forum 2008, 35:635-642.
138. Penn I. Depressed immunity and the development of cancer. Clin. Exp. Immunol. 1981, 46:459-474.
139. Petrovsky N., Harrison L. Diurnal rhythmicity of human cytokine production: a dynamic disequilibrium in T helper cell type 1/T helper cell type 2 balance?. J. Immunol. 1997, 158:5163-5168.
140. Prinz P., Bailey S., Moe K., Wilkinson C., Scanlan J. Urinary free cortisol and sleep under baseline and stressed conditions in healthy senior women: effects of estrogen replacement therapy. J. Sleep Res. 2001, 10:19-26.
141. Pyter L., Pineros V., Galang J., McClintock M., Prendergast B. Peripheral tumors induce depressive-like behaviors and cytokine production and alter hypothalamic-pituitary-adrenal axis regulation. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:9069-9074.
142. Reiche E., Nunes S., Morimoto H. Stress, depression, the immune system, and cancer. Lancet Oncol. 2004, 5:617-625.
143. Rich T., Innominato P., Boerner J., Mormont M.C., Iacobelli S., Baron B. Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin. Cancer Res. 2005, 11:1757-1764.
144. Rosenfeld P., Van Eekelen J., Levine S., De Kloet E. Ontogeny of the type 2 glucocorticoid receptor in discrete rat brain regions: An immunocytochemical study. Dev. Brain Res. 1988, 42:119-127.
145. Rubio M., Werbajh S., Cafferata E., Quaglino A., Coló G., Nojek I. TNF-α enhances estrogen-induced cell proliferation of estrogen-dependent breast tumor cells through a complex containing nuclear factor-kappa B. Oncogene 2006, 25:1367-1377.
146. Salgado R., Junius S., Benoy I., Van Dam P., Vermeulen P., Van Marck E. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int. J. Cancer 2003, 103:642-646.
147. Sanchez-Barcelo E., Cos S., Fernandez R., Mediavilla M. Melatonin and mammary cancer: a short review. Endocrinol. Relat. Cancer 2003, 10:153-159.
148. Schernhammer E., Berrino F., Krogh V., Secreto G., Micheli A., Venturelli E. Urinary 6-sulfatoxymelatonin levels and risk of breast cancer in postmenopausal women. J. Natl. Cancer Inst. 2008, 100:898-905.
149. Schernhammer E., Hankinson S. Urinary melatonin levels and breast cancer risk. J. Natl. Cancer Inst. 2005, 97:1084-1087.
150. Schernhammer E., Kroenke C., Laden F., Hankinson S. Night work and risk of breast cancer. Epidemiology 2006, 17:108-111.
151. Schernhammer E., Laden F., Speizer F., Willett W., Hunter D., Kawachi I. Rotating night shifts and risk of breast cancer in women participating in the nurses' health study. J. Natl. Cancer Inst. 2001, 93:1563-1568.
152. Schernhammer E., Laden F., Speizer F., Willett W., Hunter D., Kawachi I. Night-shift work and risk of colorectal cancer in the Nurses' Health Study. J. Natl. Cancer Inst. 2003, 95:825-828.
153. Schibler U., Sassone-Corsi P. A web of circadian pacemakers. Cell 2002, 111:919-922.
154. Schmiegelow K., Glomstein A., Kristinsson J., Salmi T., Schroder H., Bjork O. Impact of morning versus evening schedule for oral methotrexate and 6-mercaptopurine on relapse risk for children with acute lymphoblastic leukemia. J. Pediatr. Hematol. Oncol. 1997, 19:102-109.
155. Sephton S., Sapolsky R., Kraemer H., Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. J. Natl. Cancer Inst. 2000, 92:994-1000.
156. Sephton S., Spiegel D. Circadian disruption in cancer: a neuroendocrine-immune pathway from stress to disease? Brain Behav. Immun. 2003, 17:321-328.
157. Sgoifo A., Buwalda B., Roos M., Costoli T., Merati G., Meerlo P. Effects of sleep deprivation on cardiac autonomic and pituitary-adrenocortical stress reactivity in rats. Psychoneuroendocrinology 2006, 31:197-208.
158. Shimizu J., Yamazaki S., Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: A common basis between tumor immunity and autoimmunity. J. Immun. 1999, 163:5211-5218.
159. Sica A., Saccani A., Bottazzi B., Polentarutti N., Vecchi A., van Damme J. Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. J. Immunol. 2000, 164:762-767.
160. Soloski M. Recognition of tumor cells by the innate immune system. Curr. Opin. Immunol. 2001, 13:154-162.
161. Son G., Chung S., Choe H., Kim H., Baik S., Lee H. Adrenal peripheral clock controls the autonomous circadian rhythm of glucocorticoid by causing rhythmic steroid production. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:20970-20975.
162. Sood A., Bhatty R., Kamat A., Landen C., Han L., Thaker P. Stress hormone-mediated invasion of ovarian cancer cells. Clin. Cancer Res. 2006, 12:369-375.
163. Sorrells S., Sapolsky R. An inflammatory review of glucocorticoid actions in the CNS. Brain Behav. Immun. 2007, 21:259-272.
164. Spiegel D., Giese-Davis J. Depression and cancer: mechanisms and disease progression. Biol. Psychiatry 2003, 54:269-282.
165. Spiegel D., Giese-Davis J., Taylor C., Kraemer H. Stress sensitivity in metastatic breast cancer: Analysis of hypothalamic-pituitary-adrenal axis function. Psychoneuroendocrinology 2006, 31:1231-1244.
166. Spiegel D., Sephton S. Re: night shift work, light at night, and risk of breast cancer. J. Natl. Cancer Inst. 2002, 94:530.
167. Spiegel K., Sheridan J., Van Cauter E. Effect of sleep deprivation on response to immunization. J. Am. Med. Assoc. 2002, 288:1471-1472.
168. Stevens R. Light-at-night, circadian disruption and breast cancer: assessment of existing evidence. Int. J. Epidemiol. Epub 2009.
169. Suzuki S., Toyabe S., Moroda T., Tada T., Tsukahara A., Ilai T. Circadian rhythm of leucocytes and lymphocyte subsets and its possible correlation with the function of the autonomic nervous system. Clin. Exp. Immunol. 1997, 110:500-508.
170. Tamarkin L., Danforth D., Lichter A., DeMoss E., Cohen M., Chabner B. Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer. Science 1982, 216:1003-1005.
171. Thaker P., Han L., Kamat A., Arevalo J., Takahashi R., Lu C. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat. Med. 2006, 12:939-944.
172. Thaker P., Sood A. Neuroendocrine influences on cancer biology. Semin. Cancer Biol. 2008, 18:164-170.
173. Touitou Y., Lévi F., Bogdan A., Benavides M., Bailleul F., Misset J. Rhythm alteration in patients with metastatic breast cancer and poor prognostic factors. J. Cancer Res. Clin. Oncol. 1995, 121:181-188.
174. Trzonkowski P., Szmit E., Myśliwska J., Dobyszuk A., Myśliwski A. CD4+CD25+T regulatory cells inhibit cytotoxic activity of T CD8+ and NK lymphocytes in the direct cell-to-cell interaction. Clin. Immunol. 2004, 112:258-267.
175. Turner-Cobb J., Sephton S., Koopman C., Blake-Mortimer J., Spiegel D. Social support and salivary cortisol in women with metastatic breast cancer. Psychosom. Med. 2000, 62:337-345.
176. Vandewalle B., Revillion F., Lefebvre J. Functional β-adrenergic receptors in breast cancer cells. J. Cancer Res. Clin. Oncol. 1990, 116:303-306.
177. Van Reeth O., Weibel L., Spiegel K., Leproult R., Dugovic C., Maccari S. Physiology of sleep. Interactions between stress and sleep: from basic research to clinical situations. Sleep Med. Rev. 2000, 4:201-219.
178. Vedhara K., Stra J., Miles J., Sanderman R., Ranchor A. Psychosocial factors associated with indices of cortisol production in women with breast cancer and controls. Psychoneuroendocrinology 2006, 31:299-311.
179. Vgontzas A., Mastorakos G., Bixler E., Kales A., Gold P., Chrousos G. Sleep deprivation effects on the activity of the hypothalamic-pituitary-adrenal and growth axes: potential clinical implications. Clin. Endocrinol. 1999, 51:205-215.
180. Viswanathan A., Hankinson S., Schernhammer E. Night shift work and the risk of endometrial cancer. Cancer Res. 2007, 67:10618-10622.
181. Von Ah D., Kang D., Carpenter J. Stress, optimism, and social support: impact on immune responses in breast cancer. Res. Nurs. Health 2007, 30:72-83.
182. Voronov E., Shouval D., Krelin Y., Cagnano E., Benharroch D., Iwakura Y. IL-1 is required for tumor invasiveness and angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:2645-2650.
183. Waldmann T. Immunotherapy: past, present and future. Nat. Med. 2003, 9:269-277.
184. Webster J., Tonelli L., Sternberg E. Neuroendocrine regulation of immunity. Ann. Rev. Immunol. 2002, 20:125-163.
185. Winter S., Bosnoyan-Collins L., Pinnaduwage D., Andrulis I. Expression of the circadian clock genes Per1 and Per2 in sporadic and familial breast tumors. Neoplasia 2007, 9:797-800.
186. Wood P., Yang X., Taber A., Oh E., Ansell C., Ayers S. Period 2 mutation accelerates ApcMin/+ tumorigenesis. Mol. Cancer Res. 2008, 6:1786-1793.
187. Yamamoto T., Nakahata Y., Soma H., Akashi M., Mamine T., Takumi T. Transcriptional oscillation of canonical clock genes in mouse peripheral tissues. BMC Mol. Biol. 2004, 5:18-27.
188. Yang X., Wood P., Oh E., Du-Quiton J., Ansell C., Hrushesky W. Down regulation of circadian clock gene Period 2 accelerates breast cancer growth by altering its daily growth rhythm. Breast Cancer Res. Treat. 2009, 117:423-431.
189. Yang X., Wood P., Ansell C., Quiton D., Oh E., Du-Quiton J. The circadian clock gene Per1 suppresses cancer cell proliferation and tumor growth at specific times of day. Chronobiol. Int. 2009, 26:1323-1339.
190. Yi C., Mu L., de la Longrais I., Sochirca O., Arisio R., Yu H. The circadian gene NPAS2 is a novel prognostic biomarker for breast cancer. Breast Cancer Res. Treat. Epub 2009.
191. Yin D., Tuthill D., Mufson A., Shi Y. Chronic restraint stress promotes lymphocyte apoptosis by modulating CD95 expression. J. Exp. Med. 2000, 191:1423-1428.
192. You S., Wood P., Xiong Y., Kobayashi M., Du-Quiton J., Hrushesky W. Daily coordination of cancer growth and circadian clock gene expression. Breast Cancer Res. Treat. 2005, 91:47-60.
193. Zager A., Andersen M., Ruiz F., Antunes I., Tufik S. Effects of acute and chronic sleep loss on immune modulation of rats. Am. J. Physio. Regul. Integr. Comp. Physiol. 2007, 293:R504-R509.
194. Zhdanova I., Tucci V. Melatonin, circadian rhythms, and sleep. Curr. Treat. Options Neurol. 2003, 5:225-229.
195. Zhu Y., Brown H., Zhang Y., Stevens R., Zheng T. Period3 structural variation: a circadian biomarker associated with breast cancer in young women. Cancer Epidemiol. Biomarkers Prev. 2005, 14:268-270.
196. Zhu Y., Stevens R., Leaderer D., Hoffman A., Holford T., Zhang Y. Non-synonymous polymorphisms in the circadian gene NPAS2 and breast cancer risk. Breast Cancer Res. Treat. 2008, 107:421-425.